The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
| Status: | Withdrawn |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Ocular, Ocular, Ocular, Endocrine |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Endocrinology, Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/17/2018 |
| Start Date: | June 2014 |
| End Date: | December 2016 |
The purpose of this study is to evaluate the potential secondary beneficial effect of
prostaglandin analogues (PA) treatment in thyroid eye disease (TED) patients. This study aims
to determine if PA would change the course of the orbitopathy in TED patients by altering the
progression of the common features of TED, including fatty hypertrophy, proptosis, eyelid
retraction and optic nerve compression. The eyes with thyroid eye disease and elevated
intraocular pressure will be randomised to the PA treatment and the other eye will serve as a
control eye and will be treated with Timolol.
prostaglandin analogues (PA) treatment in thyroid eye disease (TED) patients. This study aims
to determine if PA would change the course of the orbitopathy in TED patients by altering the
progression of the common features of TED, including fatty hypertrophy, proptosis, eyelid
retraction and optic nerve compression. The eyes with thyroid eye disease and elevated
intraocular pressure will be randomised to the PA treatment and the other eye will serve as a
control eye and will be treated with Timolol.
Inclusion Criteria:
- mild or moderate to severe thyroid eye disease in one or both eyes
- age > 18 years
- informed consent
- intraocular pressure > 21 mmHg or glaucoma suspect or glaucoma diagnosed in one or
both eyes
- not on current prostaglandin analog intraocular pressure lowering therapy
Exclusion Criteria:
- sight threatening thyroid eye disease
- children < 18 years old
- patients that are not compliant with treatment or follow-up
- patients already on prostaglandin analog treatment
- patients that undergo cosmetic periocular procedures during the study will be excluded
from further follow up
- patients that cannot tolerate prostaglandin analog treatment.
- patients with bilateral thyroid eye disease and elevated intraocular pressures that
cannot tolerate treatment with timolol or an alternative intraocular pressure lowering
medication such as trusopt, combigan, cosopt.
We found this trial at
1
site
Click here to add this to my saved trials
